Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 07/29 10:14:59 pm
112.19 USD   +0.84%
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28 CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/28 CELGENE : beats Street 2Q forecasts
07/28 CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
07/28 CELGENE : Reports Second Quarter 2016 Operating and Financial Results
07/26 CELGENE CORP /DE/ : Other Events (form 8-K)
07/26 CELGENE : Purchase of Disconnector, knife switch and lightning rod.
More news
Sector news : Bio Therapeutic Drugs
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/29 BIOTECH FORUM DAILY DIGEST : Biotech Tries To Break Through Upward Resistance Le..
07/29 CNBC : Medivation sets mid-August deadline; SNY, PFE, GILD, CELG in play
07/28 Celgene (CELG) Mark J. Alles on Q2 2016 Results - Earnings Call Transcript
07/28 Celgene Q2 top line up 21%; EPS up 74%; EPS guidance lowered; shares up 2% pr..
07/28 Celgene beats by $0.05, beats on revenue
Advertisement
Financials ($)
Sales 2016 11 073 M
EBIT 2016 5 873 M
Net income 2016 3 416 M
Debt 2016 7 253 M
Yield 2016 -
P/E ratio 2016 27,27
P/E ratio 2017 19,91
EV / Sales 2016 8,51x
EV / Sales 2017 7,02x
Capitalization 86 960 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 138 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Jerome B. Zeldis Chief Medical Officer & CEO-Global Health
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-6.32%86 960
AMGEN, INC.5.98%129 232
GILEAD SCIENCES, INC.-21.46%105 840
REGENERON PHARMACEUTIC..-21.69%44 671
VERTEX PHARMACEUTICALS..-22.91%23 993
ACTELION LTD22.85%20 223
More Results